Sermorelin / GHRP-6 Blend
A research peptide blend combining Sermorelin (a GHRH analogue) and GHRP-6 (a synthetic ghrelin analogue), studied for synergistic enhancement of growth hormone release through complementary pituitary receptor activation.
This blend combines Sermorelin, the biologically active N-terminal 29-amino-acid fragment of growth hormone releasing hormone (GHRH), with GHRP-6, a synthetic hexapeptide ghrelin receptor agonist. The dual-receptor activation model produces synergistic GH elevation, with GHRP-6 raising trough GH levels and Sermorelin increasing peak amplitude, making this combination a well-characterized research tool for investigating GH axis physiology.
Overview
Sermorelin activates pituitary GHRH receptors to drive GH gene transcription and pulsatile secretion, while GHRP-6 binds the growth hormone secretagogue receptor (GHS-R1a) to amplify GH release through a separate intracellular signaling pathway. GHRP-6 additionally stimulates appetite via central ghrelin pathways, which may support anabolic processes downstream of elevated GH. The combination exploits the well-documented synergy between GHRH-pathway and ghrelin-pathway agonists to produce GH responses substantially greater than either agent alone.
Mechanism of Action
Sermorelin mimics endogenous GHRH by binding to GHRH-R on anterior pituitary somatotrophs, activating the cAMP/PKA pathway to stimulate GH gene transcription and exocytosis. GHRP-6 acts through the GHS-R1a receptor, engaging the PLC/IP3/PKC signaling cascade. When both pathways are activated concurrently, the result is a synergistic amplification of GH pulse amplitude that exceeds the additive effect of either agent. GHRP-6 also acts centrally to stimulate appetite through hypothalamic ghrelin receptor activation, distinguishing it from more selective GH secretagogues like ipamorelin.
Reconstitution Calculator
Sermorelin / GHRP-6 Blend
This blend combines Sermorelin, the biologically active N-terminal 29-amino-acid
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Synergistic GH Release
The synergistic interaction between GHRH and GHRP pathways was established by Bowers et al. (1990), demonstrating that combined administration produced GH responses several-fold greater than either peptide alone. This synergy has been confirmed across species and is attributed to convergent signaling at the somatotroph level.
Appetite and Anabolic Effects
GHRP-6 is notable among GH secretagogues for its potent orexigenic effect. Arvat et al. (2001) characterized the GH-releasing and appetite-stimulating properties of GHRP-6 in human subjects, confirming that it activates both pituitary and hypothalamic ghrelin pathways. This appetite stimulation may complement the anabolic effects of elevated GH in catabolic or wasting conditions.
GH Deficiency Models
Research in GH-deficient animal models has shown that GHRH analogues combined with GHRPs can restore near-physiological GH pulsatility. Walker (2006) discussed the advantages of sermorelin-based approaches for managing adult-onset GH insufficiency, noting preserved feedback regulation compared to exogenous GH.
Safety Profile
Sermorelin has a well-established safety profile from clinical use, with adverse effects generally limited to injection site reactions, transient flushing, and headache. GHRP-6 may elevate cortisol, prolactin, and ACTH at higher doses. The most notable side effect specific to GHRP-6 is significant appetite stimulation, which may be desirable or undesirable depending on the research context. The combination maintains physiological GH pulsatility and negative feedback, reducing the risk of supraphysiological GH exposure. Long-term safety data for the specific blend are derived from individual component studies.
Pharmacokinetic Profile
Sermorelin / GHRP-6 Blend — Pharmacokinetic Curve
Subcutaneous injectionQuick Start
- Route
- Subcutaneous injection
Research Protocols
subcutaneous Injection
Administered via subcutaneous injection.
Interactions
Peptide Interactions
GHRP-6 also acts centrally to stimulate appetite through hypothalamic ghrelin receptor activation, distinguishing it from more selective GH secretagogues like ipamorelin.
GHRP-6 also acts centrally to stimulate appetite through hypothalamic ghrelin receptor activation, distinguishing it from more selective GH secretagogues like ipamorelin.
What to Expect
What to Expect
Rapid onset expected; half-life of Sermorelin: ~10-20 min; GHRP-6: ~2-3 hours indicates fast-acting pharmacokinetics
Due to short half-life (Sermorelin: ~10-20 min; GHRP-6: ~2-3 hours), effects are expected per-dose; consistent daily administration maintains...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
Caution
- Injection site reactions reported
Frequently Asked Questions
References (6)
- [5]Tavares et al — Ghrelin and growth hormone secretagogues: metabolic and cardiovascular effects Peptides (2023)
- [4]Donato et al — Growth hormone-releasing hormone/growth hormone secretagogue combination therapy: an updated review Endocrine (2023)
- [6]Sigalos & Pastuszak — GHS-R signaling in neuroendocrine physiology and metabolic regulation Best Practice & Research Clinical Endocrinology & Metabolism (2022)
- [1]Bowers CY et al On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone Endocrinology (1990)
- [2]Arvat E et al Endocrine activities of ghrelin, a natural growth hormone secretagogue, in humans J Clin Endocrinol Metab (2001)
- [3]Walker RF Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging (2006)
Sermorelin / GHRP-2 Blend
A research peptide blend combining Sermorelin (a GHRH analogue) and GHRP-2 (a ghrelin receptor agonist), studied for synergistic amplification of growth hormone release through dual pituitary receptor pathway activation.
Sermorelin / GHRP-6 / GHRP-2 Blend
A triple-peptide research blend combining Sermorelin (a GHRH analogue) with GHRP-6 and GHRP-2 (both ghrelin receptor agonists), studied for synergistic GH axis stimulation and complementary secondary effects on neuroprotection, wound healing, and immune function.